rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    KALA
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.41%
      Nov 16Investing.comKALA
      Kala Bio announces 1-for-30 reverse stock split effective Friday
      Nov 12Investing.comKALA
      KALA BIO Announces Reverse Stock Split

      Common Stock Will Begin Trading on a Split-Adjusted Basis on November 16, 2026Arlington, Massachusetts--(Newsfile Corp. - November 12, 2026) - KALA BIO, Inc. (NASDAQ: KALA) ("KALA BIO" or the "Company"), today announced that it intends to effect a reverse stock split of its common stock, par value $0.001 per share (the "common stock"), at a ratio of 1 post-split share for every 30 pre-split shares. The reverse stock split will become effective at 4:05 p.m. on Friday, November 13, 2026. The...

      Nov 12Yahoo FinanceKALA
      KALA BIO Provides CEO Update and Preliminary Third Quarter 2026 Financial Results
      Nov 9Yahoo FinanceKALA
      Why FingerMotion Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Kala Bio

      FingerMotion jumped 18.1% premarket after agreeing to buy Newbit Technology for $2.3M cash; NewGenIvf led gainers at 187.2%, while Silexion fell 16.6%.

      Sep 30BenzingaFNGRKALANIVF
      KALA Bio (KALA) Shares Soar 57% After Hours: Here's Why - Kala Bio (NASDAQ:KALA)

      KALA Bio shares surge after hours after signing an LOI to acquire a nationwide telehealth platform.

      Sep 30BenzingaKALA
      Kala Bio signs letter of intent to acquire telehealth firm
      Sep 29Investing.comKALA
      KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception

      Proposed Acquisition Valued at Approximately $15 Million Would Add an Established 50-State Telehealth Business, with over 90,000 clients, Focused on Peptides such as GLP-1 Weight Management, Hormone Health, Longevity and Sexual WellnessKey HighlightsTarget generated approximately $12.7 million in revenue for the trailing twelve months ended August 2026 (unaudited, as provided by Target management) and is cash-flow positiveProposed purchase price of approximately $15 million, payable in cash and.

      Sep 29Yahoo FinanceKALA
      Kala Bio signs letter of intent to expand genetic testing deal
      Sep 24Investing.comKALA
      Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products
      Sep 24Yahoo FinanceKALA
      KALA BIO Adds Healthcare Operator Yenvy Truong to Advisory Team

      Founder of The LSM Group to support KALA's growth across its existing business and potential acquisitionsNEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq: KALA) ("KALA" or the "Company") today announced that Yenvy Truong, founder of The LSM Group, has joined the Company's advisory team. Ms. Truong will support management as KALA grows its existing business and evaluates opportunities to expand it, including through acquisitions. Ms. Truong has spent roughly two decades in heal

      Sep 17Yahoo FinanceKALA
      Kala Bio signs exclusive US distribution deal with Virotek for ophthalmology genetic testing
      Sep 11Investing.comKALA
      Kala Bio Signs Exclusive U.S. Distribution Agreement for Virotek Ophthalmology Genetic Tests

      Kala Bio, Inc. (NASDAQ:KALA) and Virotek Inc.

      Sep 3Yahoo FinanceKALA
      Kala Bio secures exclusive U.S. rights to Virotek genetic tests
      Sep 3Investing.comKALA
      Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program

      Agreement Grants Kala Exclusive U.S. Rights to Market and Distribute Virotek's Ophthalmology Genomic Testing ProgramARLINGTON, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Kala Bio, Inc. (Nasdaq: KALA) ("Kala") and Virotek Inc. ("Virotek") today announced that they have finalized a definitive exclusive distribution and reseller agreement (the "Agreement") and related quality, brand, and data protection agreements. Under the Agreement, Kala will be the exclusive distributor and reseller in the Unite

      Sep 3Yahoo FinanceKALA
      Kala Bio Targets Near-Term Revenue With Virotek Ophthalmology Genetic Testing Partnership

      The proposed exclusive U. S. distribution agreement would give Kala a commercial opportunity in its established ophthalmology market while leaving Virotek responsible for laboratory operations and clinical reporting.

      Sep 1Yahoo FinanceKALA
      Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program

      ARLINGTON, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kala Bio, Inc. (Nasdaq: KALA) ("Kala") and Virotek Inc. ("Virotek"), a CLIA-registered precision health and clinical genomics company, today announced that they have entered into a letter of intent (the "LOI") outlining the principal terms under which the companies intend to negotiate a definitive agreement appointing Kala as the exclusive distributor and reseller in the United States of Virotek's genetic testing and screening program for opht

      Sep 1Yahoo FinanceKALA
      KALA BIO Faces Nasdaq Listing Compliance Uncertainty

      Detailed price information for Kala Bio Inc (KALA-Q) from The Globe and Mail including charting and trades.

      Aug 29The Globe and MailKALA

      This is the newest page. Registered accounts read further back.